445 related articles for article (PubMed ID: 22805616)
1. 2012 update on diabetic kidney disease: the expanding spectrum, novel pathogenic insights and recent clinical trials.
Fernández Fernández B; Elewa U; Sánchez-Niño MD; Rojas-Rivera JE; Martin-Cleary C; Egido J; Ortiz A
Minerva Med; 2012 Aug; 103(4):219-34. PubMed ID: 22805616
[TBL] [Abstract][Full Text] [Related]
2. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
Vogt L; Kocks MJ; Laverman GD; Navis G
Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
[TBL] [Abstract][Full Text] [Related]
3. Update of pathophysiology and management of diabetic kidney disease.
Lin YC; Chang YH; Yang SY; Wu KD; Chu TS
J Formos Med Assoc; 2018 Aug; 117(8):662-675. PubMed ID: 29486908
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Dual Blockade of the Renin-Angiotensin-Aldosterone System in Diabetic Kidney Disease: A Meta-Analysis.
Feng Y; Huang R; Kavanagh J; Li L; Zeng X; Li Y; Fu P
Am J Cardiovasc Drugs; 2019 Jun; 19(3):259-286. PubMed ID: 30737754
[TBL] [Abstract][Full Text] [Related]
5. Emerging therapeutic strategies in diabetic nephropathy.
Ravera M; Re M; Weiss U; Deferrari L; Deferrari G
J Nephrol; 2007; 20 Suppl 12():S23-32. PubMed ID: 18050139
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic effects of angiotensin II inhibition or blockade on the progression of chronic renal disease.
Cantarovich F; Rangoonwala B
Int J Clin Pract; 2003 Nov; 57(9):801-22. PubMed ID: 14686572
[TBL] [Abstract][Full Text] [Related]
7. Albuminuria: a target for treatment of type 2 diabetic nephropathy.
de Zeeuw D
Semin Nephrol; 2007 Mar; 27(2):172-81. PubMed ID: 17418686
[TBL] [Abstract][Full Text] [Related]
8. Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone.
Schjoedt KJ; Jacobsen P; Rossing K; Boomsma F; Parving HH
Horm Metab Res; 2005 Apr; 37 Suppl 1():4-8. PubMed ID: 15918104
[TBL] [Abstract][Full Text] [Related]
9. Novel effective drugs for diabetic kidney disease? or not?
Gentile G; Mastroluca D; Ruggenenti P; Remuzzi G
Expert Opin Emerg Drugs; 2014 Dec; 19(4):571-601. PubMed ID: 25376947
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
Hughes DB; Britton ML
Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022
[TBL] [Abstract][Full Text] [Related]
11. Preserving the diabetic kidney.
Poirier SJ
J Fam Pract; 1998 Jan; 46(1):21-7. PubMed ID: 9451365
[TBL] [Abstract][Full Text] [Related]
12. Intervention using vitamin D for elevated urinary albumin in type 2 diabetes mellitus (IDEAL-2 Study): study protocol for a randomised controlled trial.
Taheri S; Asim M; Al Malki H; Fituri O; Suthanthiran M; August P;
Trials; 2018 Apr; 19(1):230. PubMed ID: 29665833
[TBL] [Abstract][Full Text] [Related]
13. Preventing end-stage renal disease in diabetic patients - dual blockade of the renin-angiotensin system (Part II).
Jacobsen PK
J Renin Angiotensin Aldosterone Syst; 2005 Sep; 6(2):55-68. PubMed ID: 16470484
[TBL] [Abstract][Full Text] [Related]
14. Early renin-angiotensin system intervention is more beneficial than late intervention in delaying end-stage renal disease in patients with type 2 diabetes.
Schievink B; Kröpelin T; Mulder S; Parving HH; Remuzzi G; Dwyer J; Vemer P; de Zeeuw D; Lambers Heerspink HJ
Diabetes Obes Metab; 2016 Jan; 18(1):64-71. PubMed ID: 26434564
[TBL] [Abstract][Full Text] [Related]
15. Renin-Angiotensin-Aldosterone system blockade in diabetic kidney disease: A critical and contrarian point of view.
Elrggal ME; Ahmed SM; El Nahas M
Saudi J Kidney Dis Transpl; 2016; 27(6):1103-1113. PubMed ID: 27900954
[TBL] [Abstract][Full Text] [Related]
16. The renin-angiotensin-aldosterone system and its blockade in diabetic nephropathy: main focus on the role of aldosterone.
Schjoedt KJ
Dan Med Bull; 2011 Apr; 58(4):B4265. PubMed ID: 21466768
[TBL] [Abstract][Full Text] [Related]
17. Present and future in the treatment of diabetic kidney disease.
Quiroga B; Arroyo D; de Arriba G
J Diabetes Res; 2015; 2015():801348. PubMed ID: 25945357
[TBL] [Abstract][Full Text] [Related]
18. Slowing progression along the renal disease continuum.
Kopyt NP
J Am Osteopath Assoc; 2005 Apr; 105(4):207-15. PubMed ID: 15928338
[TBL] [Abstract][Full Text] [Related]
19. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
[TBL] [Abstract][Full Text] [Related]
20. [Risk and prevention of diabetic nephropathy].
Ravera M; Re M; Deferrari G
G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
